• In early June 2026, uniQure disclosed that the FDA had rejected its data package for accelerated approval of AMT-130 in Huntington’s disease, instead advising a new, lengthy Phase III sham-controlled trial that will delay any potential path to market.
• This shift forces uniQure to reconsider the role of AMT-130 as its lead value driver, given the extended timelines, higher costs, and added clinical and regulatory uncertainty.
• We’ll now examine how the FDA’s push for a new Phase III sham-controlled trial reshapes uniQure’s investment narrative and risk profile.

Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

uniQure Investment Narrative Recap

To own uniQure today, you need to believe that its gene therapy platform can eventually translate into approved products despite long timelines, heavy losses and regulatory setbacks. The FDA’s rejection of accelerated approval for AMT-130 directly hits the key near term catalyst and keeps the company’s biggest risk front and center: that its lead program may require more time, capital and data before regulators are prepared to approve it.

The April 30, 2026 update on AMT-130, highlighting plans to submit a UK MAA in Q3 2026 based on three year Phase I/II data, now looks different in light of the FDA’s stance. While UK and EU pathways may still offer nearer term regulatory milestones, the new US Phase III requirement underlines that any broader commercial opportunity will likely hinge on successfully executing larger trials and managing cash burn in the process.

Yet behind the scientific promise, investors also need to be aware of litigation and regulatory scrutiny around how AMT-130 data have been communicated, because...

uniQure's narrative projects $200.2 million revenue and $38.1 million earnings by 2029. This requires 122.8% yearly revenue growth and a $247.0 million earnings increase from -$208.9 million today.

Uncover how uniQure's forecasts yield a $39.05 fair value, a 48% upside to its current price.

Exploring Other Perspectives

Before this setback, the most optimistic analysts were assuming uniQure could reach about US$595.5 million in revenue and US$165.6 million in earnings by 2029, which is a very different story to today and shows how widely views can differ and may still change as the AMT-130 risk around additional costly trials becomes clearer.

Explore 5 other fair value estimates on uniQure - why the stock might be worth just $33.36!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your uniQure research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free uniQure research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate uniQure's overall financial health at a glance.

No Opportunity In uniQure?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.